Bernd Christensen

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Sex Differences in Posttraumatic Cytokine Release of Endotoxin-Stimulated Whole Blood: Relationship to the Development of Severe Sepsis

Matthias Majetschak, Bernd Christensen, U. Obertacke et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 2000 · 103 citations

Veterinary Medicine, Immunology, Pathology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

High-dose pilot study with the novel progestogen dienogestin patients with endometriosis

A. E. Schindler, Bernd Christensen, Alexandra Henkel et al. · Gynecological Endocrinology · 2006 · 53 citations

Medicine, Gynecology, Pharmacotherapy +13